Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.